Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 37 EP824 | DOI: 10.1530/endoabs.37.EP824

Pituitary: clinical

A rare case of GH deficiency: mucolipidoses type II/III

Elena Braha1,2, Ioana Armasu2, Cristina Rusu1, Daniela Raileanu3, Adina Manolachie2, Georgiana Constantinescu2, Mirela Puiu2, Roxana Stefan2 & Carmen Vulpoi2

22 views


1Department of Genetics, University of Medicine and Pharmacy ‘Gr.T. Popa’, Iasi, Romania; 2Department of Endocrinology, University of Medicine and Pharmacy ‘Gr.T. Popa’, Iasi, Romania; 3County Hospital, Botosani, Romania.


Introduction: Mucolipidoses II/III (ML) are rare autosomal recessive lysosomal storage disorders (incidence: 1/325 000 live births). They have overlapping clinical phenotypes with mucopolysaccharidosis disorders and include growth retardation, facial dysmorphism, skeletal abnormalities, respiratory and heart diseases, hepatosplenomegaly and abdominal hernias. There is no specific treatment and the management has been limited to supportive care.

Case presentation: A Manolachie aged 18, boy of an young non-consanguineous apparently healthy couple, in evidence of the Genetics Department for mucopolysaccharidosis type I, was first addressed to the Endocrinology Department at the age of 14 years 4 months for investigations of growth retardation. The clinical examination revealed short stature (−4 S.D.), ‘elf’ facies, limited extension and abduction of the upper limbs with bilateral tendon retraction of the fingers and also in the radiocarpal and elbow joints, decreased mobility of the spine and waddling walk with wide support base; no signs of pubertal onset. Wrist radiography revealed delayed bone age of ~6 years. Somatotropic axis investigations revealed low IGF1 (62.4 ng/ml, n=220–972, GH=0.42 ng/ml, without stimulation at the arginine test: GH=2.75 ng/ml) pleading for GH deficiency. Since there were not known contraindications, GH replacement therapy was started with an initial dose of 0.035 mg/kg per day and biannual reassessments were performed. After 4 years of treatment the medium growth rate was 0.42 cm/month and no side effects were reported. The last wrist radiography revealed delayed bone age (11 years and 6 months) permitting treatment continuation. At the last evaluation the enzymes α-iduronidase, iduronate-2-sulfatase, arylsulfatase B, β-galactosidase could be assessed and were indicative of MLV II/III.

Conclusions: Corroborating the clinical phenotype, biological data and evolution, this case can be included in MLV III. We haven’t found in the literature any case of MLV III treated with GH replacement therapy. In our case the treatment was effective and improved the patient’s quality of life.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.